BEVACIZUMAB IN RECURRENT MALIGNANT GLIOMA, A SINGLE INSTITUTION EXPERIENCE

被引：0
|
作者：
Cunha, J. [1 ]
Almeida, M. [1 ]
Couto, E. [1 ]
Amorim, J. [1 ]
Nabico, R. [1 ]
机构：
[1] Hosp Braga, Braga, Portugal
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P09.06
引用
收藏
页码：71 / 71
页数：1
相关论文
共 50 条
  • [41] MALIGNANT HEMOPERITONEUM IN CHILDREN: A SINGLE INSTITUTION EXPERIENCE
    Palacios, J.
    Shalkow, J.
    Guzman, I.
    Leon, A.
    Vazquez, J.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S146 - S146
  • [42] A single institution experience of the incidence of extracranial metastasis in glioma
    Amitendu, Sekhar
    Mak, Siu Kei David
    Ling, Ji Min
    Ng, Wai Hoe
    JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (11) : 1511 - 1515
  • [43] FRACTIONATED STEREOTACTIC RADIOTHERAPY FOLLOWED BY RESUMPTION OF BEVACIZUMAB IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA AND PROGRESSIVE DISEASE ON BEVACIZUMAB
    Glass, Jon
    Andrews, David W.
    Werner-Wasik, Maria
    Evans, James
    Lawrence, Yaakov R.
    Shi, Wenyin
    NEURO-ONCOLOGY, 2011, 13 : 131 - 131
  • [44] Re-irradiation for Recurrent Glioma: A Single Institution Review
    Harris, T. J.
    Kleinberg, L. R.
    McMillan, R.
    Terezakis, S.
    Holdhoff, M.
    Lim, M.
    Redmond, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S257 - S257
  • [45] Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.
    Cha, Yongjun
    Kim, Yu Jung
    Kim, Tae Min
    Choi, Seung Hong
    Lee, Se-Hoon
    Kim, Dong-Wan
    Park, Chul-Kee
    Kim, Il Han
    Kim, Jee Hyun
    Kim, Eunhee
    Choi, Byung Se
    Kim, Chae-yong
    Kim, In Ah
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
    Cha, Yongjun
    Kim, Yu Jung
    Lee, Se-Hoon
    Kim, Tae-Min
    Choi, Seung Hong
    Kim, Dong-Wan
    Park, Chul-Kee
    Kim, Il Han
    Kim, Jee Hyun
    Kim, Eunhee
    Choi, Byungse
    Kim, Chae-Yong
    Kim, In Ah
    Heo, Dae Seog
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 129 - 140
  • [47] Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
    Quant, Eudocia C.
    Norden, Andrew D.
    Drappatz, Jan
    Muzikansky, Alona
    Doherty, Lisa
    LaFrankie, Debra
    Ciampa, Abigail
    Kesari, Santosh
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2009, 11 (05) : 550 - 555
  • [48] Assessment of treatment response to bevacizumab (BEV) with MRI in recurrent malignant glioma (MG)
    Mohile, Nimish
    Abrey, Lauren
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [49] Predictive biomarkers for Bevacizumab activity in recurrent glioblastoma: A single institution study
    Dragan, Marcin
    Carli, Matthew
    Malkin, Mark
    Yazbeck, Victor
    CANCER RESEARCH, 2020, 80 (16)
  • [50] TOXICITY PROFILE OF BEVACIZUMAB BASED REGIMENS IN THE TREATMENT OF PEDIATRIC MALIGNANT BRAIN TUMORS - A SINGLE INSTITUTION'S EXPERIENCE
    Huynh, V. T.
    Templeman, T.
    Shen, V.
    NEURO-ONCOLOGY, 2010, 12 (06) : II90 - II90
12345